• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ACELYRIN, INC. - Common Stock (NQ: SLRN )

    2.040 +0.140 (+7.37%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 16,473,804
    Open 2.020
    Bid (Size) 2.020 (12)
    Ask (Size) 2.100 (50)
    Prev. Close 1.900
    Today's Range 1.950 - 2.280
    52wk Range 1.855 - 8.885
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders
    From Ademi & Fruchter LLP
    Via Business Wire

    Performance

    YTD
    -38.18%
    -38.18%
    1 Month
    -0.97%
    -0.97%
    3 Month
    -66.34%
    -66.34%
    6 Month
    -55.26%
    -55.26%
    1 Year
    -73.68%
    -73.68%

    More News

    Read More
    Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
    From ACELYRIN, INC.
    Via GlobeNewswire
    Nasdaq Down 1.5%; RPM Posts Upbeat Results
    Via Benzinga
    Earnings Scheduled For November 13, 2024
    Via Benzinga
    Earnings Preview: Acelyrin
    Via Benzinga
    SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
    Via InvestorPlace
    Dow Surges Over 100 Points; US Trade Deficit Widens In November
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
    From ACELYRIN, INC.
    Via GlobeNewswire
    What's Going On With ACELYRIN Shares Friday?
    Via Benzinga
    Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
    From ACELYRIN, INC.
    Via GlobeNewswire
    Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. to Participate in Upcoming Investor Conferences
    From ACELYRIN, INC.
    Via GlobeNewswire
    Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
    Via Benzinga
    Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.